UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mantle cell lymphoma and its management: where are we now?

Experimental hematology & oncology, 2019-01, Vol.8 (1), p.2-2, Article 2

2019

Volltextzugriff (PDF)

Mantle cell lymphoma management trends and novel agents: where are we going?

Therapeutic advances in hematology, 2022-02, Vol.13, p.20406207221080743-20406207221080743

2022

Volltextzugriff (PDF)

Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B‐cell non‐Hodgkin lymphoma and previously untreated mantle cell lymphoma

British journal of haematology, 2019-09, Vol.186 (6), p.845-854

2019

Volltextzugriff (PDF)

The Results of a Phase I Study using Velcade (Bortezomib), Cladribine, and Rituximab (VCR) in treating Mantle Cell Lymphoma

Blood, 2016-12, Vol.128 (22), p.1792-1792

2016

Volltextzugriff (PDF)

Marginal zone lymphoma: old, new, targeted, and epigenetic therapies

Therapeutic Advances in Hematology, 2012-10, Vol.3 (5), p.275-290

2012

Volltextzugriff (PDF)

The Final Results of a Phase I Study Using Bortezomib (Velcade), Cladribine, and Rituximab (VCR) in Treating Mantle Cell Lymphoma

Blood, 2023-11, Vol.142 (Supplement 1), p.6152-6152

2023

Volltextzugriff (PDF)

Life-Threatening Adenovirus Infections in the Setting of the Immunocompromised Allogeneic Stem Cell Transplant Patients

Advances in Hematology, 2010, Vol.2010 (2010), p.183-187

2010

Volltextzugriff (PDF)

Abstract CT145: The final results of a phase I study using velcade (bortezomib), cladribine, and rituximab (VCR) in treating elderly patient with mantle cell lymphoma

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT145-CT145

2024

Volltextzugriff (PDF)

The Mantle Cell Lymphoma Response to VCR Protocol Associated with Its Sensitivity to Hypomethylation Regulation-a Collateral Study on VCR Phase I Trial

Blood, 2018-11, Vol.132 (Supplement 1), p.5295-5295

2018

Volltextzugriff (PDF)

Overcoming Ibrutinib Resitance In Relapsed Chronic Lymphocytic Leukemia

Blood, 2013-11, Vol.122 (21), p.4891-4891

2013

Volltextzugriff (PDF)

Crosstalk Between Cyclins D1 and D3 in Mantle Cell Level At the Transcriptional and Postranscriptional Levels

Blood, 2011-11, Vol.118 (21), p.1373-1373

2011

Volltextzugriff (PDF)

Mantle Cell Lymphoma of the Gastrointestinal Tract: A Case Series and Review of the Literature for Gastroenterologists: 1287

The American journal of gastroenterology, 2013-10, Vol.108, p.S380

2013

Volltextzugriff (PDF)

Combination HDACi and mTOR inhibitor therapy in poor-risk de novo and refractory elderly patients with AML

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e18012-e18012

2013

Volltextzugriff (PDF)

Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin’s Lymphoma and Previously Untreated Mantle Cell Lymphoma

Blood, 2014-12, Vol.124 (21), p.1714-1714

2014

Volltextzugriff (PDF)

Combined Epigenetic and Immunotherapy For Newly Diagnosed Mantle Cell Lymphoma: Correlative Studies Suggest The Importance Of Enhanced ADCC, Mechanisms of Resistance and Cyclin D1 Nuclear Localization Genotype

Blood, 2013-11, Vol.122 (21), p.3063-3063

2013

Volltextzugriff (PDF)

Epigenetic Modulation of CD30 Gene Expression in Alemtuzumab Resistant T Cell Malignancy:Rationale and Efficacy of Brentuximab Vedotin

Blood, 2012-11, Vol.120 (21), p.2454-2454

2012

Volltextzugriff (PDF)

Establishment of a New Mantle Cell Lymphoma Cell Line That Has Epigenetically Silenced CD20 As a Resistance Mechanism in Vivo

Blood, 2012-11, Vol.120 (21), p.4619-4619

2012

Volltextzugriff (PDF)

Epigenetically induced expression of CD30 in T-PLL: A rationale for the use of brentuximab vedotin

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.6616-6616

2012

Volltextzugriff (PDF)

A retrospective study analyzing activity of ofatumumab in blastic variant mantle cell lymphoma

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e18500-e18500

2012

Volltextzugriff (PDF)

Combination Therapy with Cladribine, Vorinostat, and Ofatumumab Achieves Complete Hematologic Remission in Refractory Classical Hairy Cell Leukemia

Blood, 2011-11, Vol.118 (21), p.4622-4622

2011

Volltextzugriff (PDF)

A phase II pilot efficacy trial of the combination regimen peg asparaginase/peg liposomal doxorubicin/dexamethasone (ODD) in patients with refractory lymphoid malignancies (NCT00837200)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e19502-e19502

2013

Volltextzugriff (PDF)

Abstract LB-140: Combined epigenetic and immunotherapy produces dramatic responses in 100% of newly diagnosed mantle cell lymphoma patients

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.LB-140-LB-140

2013

Volltextzugriff (PDF)

Vorinostat (SAHA), Cladribine, and Rituximab in Previously Untreated Mantle Cell Lymphoma: Updated Results From a Phase I/II Trial

Blood, 2012-11, Vol.120 (21), p.3675-3675

2012

Volltextzugriff (PDF)

Epigenetic Modulation of Alemtuzumab Mediated Antileukemia Effects and Resistance in T- Cell Prolymphocytic Leukemia

Blood, 2011-11, Vol.118 (21), p.2440-2440

2011

Volltextzugriff (PDF)

The Epigenetics of Gastrointestinal Malignancies

Current colorectal cancer reports, 2012-12, Vol.8 (4), p.254-262

2012

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(50)

Publikationsform

Sprache

Englisch
(53)

Erscheinungsjahr

n.n

Thema

Hematology
(6)
Life Sciences & Biomedicine
(6)
Science & Technology
(6)
Epigenetics
(4)
Dna Methylation
(3)
Immunotherapy
(3)
Lymphoma
(3)
Mantle Cell Lymphoma
(3)
Cladribine
(2)
Monoclonal Antibodies
(2)
Non-Hodgkin's Lymphoma
(2)
Oncology
(2)
Review
(2)
Targeted Cancer Therapy
(2)
Acetylation
(1)
Adenovirus
(1)
Allogeneic Hematopoietic Stem Cell Transplant
(1)
Antigens
(1)
Antimitotic Agents
(1)
Antineoplastic Agents
(1)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mantle cell lymphoma and its management: where are we now?

Mantle cell lymphoma management trends and novel agents: where are we going?

Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B‐cell non‐Hodgkin lymphoma and previously untreated mantle cell lymphoma

The Results of a Phase I Study using Velcade (Bortezomib), Cladribine, and Rituximab (VCR) in treating Mantle Cell Lymphoma

Marginal zone lymphoma: old, new, targeted, and epigenetic therapies

The Final Results of a Phase I Study Using Bortezomib (Velcade), Cladribine, and Rituximab (VCR) in Treating Mantle Cell Lymphoma

Life-Threatening Adenovirus Infections in the Setting of the Immunocompromised Allogeneic Stem Cell Transplant Patients

Abstract CT145: The final results of a phase I study using velcade (bortezomib), cladribine, and rituximab (VCR) in treating elderly patient with mantle cell lymphoma

The Mantle Cell Lymphoma Response to VCR Protocol Associated with Its Sensitivity to Hypomethylation Regulation-a Collateral Study on VCR Phase I Trial

Overcoming Ibrutinib Resitance In Relapsed Chronic Lymphocytic Leukemia

Crosstalk Between Cyclins D1 and D3 in Mantle Cell Level At the Transcriptional and Postranscriptional Levels

Mantle Cell Lymphoma of the Gastrointestinal Tract: A Case Series and Review of the Literature for Gastroenterologists: 1287

Combination HDACi and mTOR inhibitor therapy in poor-risk de novo and refractory elderly patients with AML

Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin’s Lymphoma and Previously Untreated Mantle Cell Lymphoma

Combined Epigenetic and Immunotherapy For Newly Diagnosed Mantle Cell Lymphoma: Correlative Studies Suggest The Importance Of Enhanced ADCC, Mechanisms of Resistance and Cyclin D1 Nuclear Localization Genotype

Epigenetic Modulation of CD30 Gene Expression in Alemtuzumab Resistant T Cell Malignancy:Rationale and Efficacy of Brentuximab Vedotin

Establishment of a New Mantle Cell Lymphoma Cell Line That Has Epigenetically Silenced CD20 As a Resistance Mechanism in Vivo

Epigenetically induced expression of CD30 in T-PLL: A rationale for the use of brentuximab vedotin

A retrospective study analyzing activity of ofatumumab in blastic variant mantle cell lymphoma

Combination Therapy with Cladribine, Vorinostat, and Ofatumumab Achieves Complete Hematologic Remission in Refractory Classical Hairy Cell Leukemia

A phase II pilot efficacy trial of the combination regimen peg asparaginase/peg liposomal doxorubicin/dexamethasone (ODD) in patients with refractory lymphoid malignancies (NCT00837200)

Abstract LB-140: Combined epigenetic and immunotherapy produces dramatic responses in 100% of newly diagnosed mantle cell lymphoma patients

Vorinostat (SAHA), Cladribine, and Rituximab in Previously Untreated Mantle Cell Lymphoma: Updated Results From a Phase I/II Trial

Epigenetic Modulation of Alemtuzumab Mediated Antileukemia Effects and Resistance in T- Cell Prolymphocytic Leukemia

The Epigenetics of Gastrointestinal Malignancies

Aktive Filter

Suchergebnisse filtern